WHO launches Groundbreaking initiative to Update HIV and TB Prevention Guidelines
The World Health Association (WHO) has announced the formation of a Guideline Development Group (GDG) to create updated recommendations on antiretroviral therapy, management of vertical HIV transmission, and TB prevention in people living with HIV. This initiative aims to address critical gaps in current practices and ensure that global health strategies remain aligned with the latest scientific evidence.
The GDG, composed of experts from all WHO regions, will convene in a series of virtual sessions starting on 18 February 2025 and concluding on 27 March 2025. These sessions will focus on reviewing systematic reviews, evidence summaries, and technical updates to formulate actionable recommendations.
Key Objectives of the Initiative
Table of Contents
The primary goal of this initiative is to develop new recommendations on the use of newer antiretroviral drugs or regimens for HIV treatment. Additionally,the GDG will update existing guidelines on preferred drugs for second- and third-line ART,prophylactic regimens,and breastfeeding practices for infants at risk of vertical transmission. The group will also evaluate tuberculosis preventive therapy (TPT) for people living with HIV who are on antiretroviral treatment.
Specific objectives include:
- Reviewing evidence to support new and updated recommendations.
- assessing benefits versus harms, values and preferences, feasibility, resource use, equity, and cost.
- Formulating recommendations for the PICO framework.
Composition of the Guideline Development Group
in line with WHO guidelines for developing recommendations,the GDG comprises members selected for their technical expertise,roles as end-users (such as program managers and healthcare providers),and representation of affected communities. these members serve in their individual capacities and do not receive financial compensation for their contributions.
Call for Public Feedback
To ensure openness and inclusivity, WHO is inviting the public and interested organizations to review the biographies of the GDG members and provide feedback.Comments can be submitted via email to [email protected] by 17 February 2025. This feedback will play a crucial role in shaping high-quality guidelines that reflect diverse perspectives and meet the needs of communities worldwide.
Key Dates and Focus Areas
| Date | Focus Area |
|——————-|——————————————————————————-|
| 18-20 Feb 2025 | Review of evidence for new antiretroviral drugs and regimens |
| 25-26 Feb 2025 | Updates on second- and third-line ART and prophylactic regimens |
| 4-5 Mar 2025 | Breastfeeding practices for infants at risk of vertical transmission |
| 25-27 Mar 2025 | Tuberculosis preventive therapy (TPT) for people living with HIV |
This initiative underscores WHO’s commitment to advancing global health by ensuring that HIV and TB prevention strategies are evidence-based, equitable, and responsive to the evolving needs of affected populations.
For more details on the Guideline Development Group and its objectives, visit the WHO declaration.
Advancing Global health: A Deep Dive into WHO’s Updated HIV and TB prevention Guidelines
The World Health Organization (WHO) has taken a monumental step forward in the fight against HIV and tuberculosis (TB) with the formation of a Guideline Development Group (GDG). This initiative aims to update global recommendations on antiretroviral therapy (ART),vertical HIV transmission management,and TB prevention for people living with HIV. To shed light on this critical development, we sat down with Dr. amina Patel,a leading infectious disease specialist and member of the GDG,to discuss the initiative’s goals,challenges,and potential impact.
The Rationale Behind the updated Guidelines
Editor: dr. Patel, thank you for joining us. To start, can you explain the key reasons behind WHO’s decision to update the HIV and TB prevention guidelines?
Dr. Patel: Thank you for having me. The decision stems from the rapid advancements in antiretroviral drugs and the evolving landscape of HIV and TB management. Newer medications and regimens have shown promising results in improving patient outcomes and reducing transmission rates. Additionally, the global health community has identified critical gaps in current guidelines, particularly in areas like second- and third-line ART, prophylactic regimens, and vertical transmission prevention. These updates aim to ensure that all affected populations have access to the most effective and equitable care.
Key Focus Areas of the Guideline Development Group
Editor: The GDG’s work will cover several critical areas. Could you elaborate on the primary focus topics?
Dr. Patel: Absolutely. The GDG’s work is divided into several key themes. Firstly, we’ll review evidence for new antiretroviral drugs and regimens to ensure they’re safe, effective, and feasible for widespread use. Secondly, we’ll update recommendations on second- and third-line ART and prophylactic regimens for individuals who don’t respond to first-line treatments. Thirdly, we’ll focus on breastfeeding practices for infants at risk of vertical HIV transmission, which is a critical area for reducing pediatric infections. we’ll evaluate tuberculosis preventive therapy (TPT) for people living with HIV, as co-infections remain a critically important global health challenge.
Ensuring Equity and Feasibility in Recommendations
Editor: How will the GDG ensure that these recommendations are equitable and feasible, especially in low-resource settings?
Dr. Patel: Equity and feasibility are at the core of our work. the GDG includes experts from all WHO regions, including representatives from low- and middle-income countries. We’ll assess each recommendation’s impact on resource use, cost-effectiveness, and healthcare infrastructure. for example, when evaluating new antiretroviral drugs, we’ll consider not just their efficacy but also their affordability and accessibility. Additionally,we’ll incorporate feedback from affected communities and healthcare providers to ensure the guidelines are practical and inclusive.
The Role of Public Feedback in Shaping the Guidelines
Editor: WHO has invited public feedback on the GDG’s work. How significant is this input, and how will it influence the final recommendations?
Dr. Patel: Public feedback is invaluable. It ensures that the guidelines reflect the needs and perspectives of the communities they’re designed to serve. By reviewing the GDG member biographies and providing input, stakeholders can highlight issues that might not have been addressed otherwise.This transparent and inclusive approach helps us create recommendations that are not only scientifically robust but also culturally sensitive and community-driven. We encourage everyone to participate and share their insights before the 17 February 2025 deadline.
the Broader Impact of Updated Guidelines
Editor: What long-term impact do you anticipate from these updated guidelines?
Dr. Patel: The potential impact is substantial. Updated guidelines can lead to better health outcomes for millions of people living with HIV and TB worldwide. By incorporating the latest scientific evidence,we can reduce transmission rates,improve treatment outcomes,and minimize the burden of co-infections.Moreover,these guidelines will guide policymakers and healthcare providers in implementing effective and equitable interventions,ultimately moving us closer to the global goals of ending HIV and TB as public health threats.
Conclusion
Editor: Thank you, Dr. Patel, for sharing your expertise and insights. It’s clear that this WHO initiative is a significant step forward in the fight against HIV and TB. We look forward to seeing the outcomes of the GDG’s work and the positive changes it will bring to global healthcare.
Dr. Patel: Thank you for the chance to discuss this vital initiative. It’s a collaborative effort that holds immense promise for improving the lives of people affected by these diseases. I’m hopeful that these updated guidelines will make a meaningful difference in the global health landscape.
